Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (411-420 of 483) with videos related to

Pageof 49
Sort By:
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialRupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, et al.
Glia|May 1, 2019
Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelinationFrancisco J Rivera, Alerie G de la Fuente, Chao Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerNancy U Lin, Véronique Diéras, Devchand Paul, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancerMartin Filipits, Torsten O Nielsen, Margaretha Rudas, et al.
Blood|May 7, 2014
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patientsMichela Tassara, Konstanze Döhner, Peter Brossart, et al.
American Journal of Hematology|March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myelomaHeinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
Nature Medicine|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trialMatthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Pageof 49

Showing results (411-420 of 483) with videos related to

Sort By:
Pageof 49
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialRupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, et al.
Glia|May 1, 2019
Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelinationFrancisco J Rivera, Alerie G de la Fuente, Chao Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerNancy U Lin, Véronique Diéras, Devchand Paul, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancerMartin Filipits, Torsten O Nielsen, Margaretha Rudas, et al.
Blood|May 7, 2014
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patientsMichela Tassara, Konstanze Döhner, Peter Brossart, et al.
American Journal of Hematology|March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myelomaHeinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
Nature Medicine|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trialMatthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Pageof 49